Download fulltext HTML
Diab, A. M. A., Suliman, E. M., Abdallah, A. H., Dyab, M. A., Awadalla, T. O. E., Kirkisawi, N. M., & Husain, N. E. O. S. A. (2017). Association between Exposure to Beta 2 Agonists and Corticosteroids and Acquiring Benign Joint Hypermobility Syndrome among Asthmatic Patients: a Case-Control Study. Sudan Journal of Medical Sciences (SJMS), 12(4), 215-230. https://doi.org/10.18502/sjms.v12i4.1353

https://doi.org/10.18502/sjms.v12i4.1353

statistics

  • 1891 Abstract Views
  • 286 PDF Views
  • 0 HTML Views

authors

  • Alsarah Mutwakil Abbas Diab
    No author data available.
  • Eman MutwakilAhmedAlmostafa Suliman
    No author data available.
  • AyatAbdallah Hassan Abdallah
    No author data available.
  • Mohamed AbdelhadiElzubair Dyab
    No author data available.
  • Tanzeel Omer Elamin Awadalla
    No author data available.
  • Naila Mubarak Kirkisawi
    No author data available.
  • Nazik Elmalaika Obaid Seid Ahmed Husain
    No author data available.

Published Date

  • Dec 28, 2017

Association between Exposure to Beta 2 Agonists and Corticosteroids and Acquiring Benign Joint Hypermobility Syndrome among Asthmatic Patients: a Case-Control Study

Sudan Journal of Medical Sciences (SJMS) / Sudan JMS: Volume 12 (2017), Issue No. 4 / Pages 215-230

Abstract

Background:Beta2 (β2) agonists as relievers and corticosteroids as controllers are the mainstay drugs for asthma treatment. Benign Joint Hypermobility Syndrome (BJHS) is a connective tissue disorder with musculoskeletal symptoms.

We had examined the possible association between the use of β2 agonists and corticosteroids and acquiring BJHS in asthmatic patients.

Methods:This was a case-control, hospital-based study including a group of asthmatics who had BJHS (cases), compared with a matched group of asthmatics without BJHS (controls) for the β2 agonists and corticosteroids past and current pattern of use. Information was collected by face-to-face interview and clinical examination and from subjects’ medical records using pre-structured questionnaire. BJHS diagnosis was based on the revised Brighton criteria. Asthma severity was reflected by a score, which was calculated from the asthma questionnaire. Comparison of exposure was done by Calculation of Odds Ratio.

Results:

Development of BJHS was found to be significantly associated with chronicity of asthma of average duration of 13.2 years, and hence to prolonged use of β2 agonists and/or corticosteroids (OR 1.019; 95% CI 0.999 - 1.039, P=0.006)

Exposure to β2 agonist and corticosteroid (87 and 79 cases and controls respectively P=0.05)high asthma score (42.9 ± 9.8 and 40.4 ± 8.3 among cases and controls respectively, P=0.011) were significantly associated with the development of BJHS.

References
[1] L. Yang, H. X. Bai, X. Huang, A. M. Lee, X. Tang, and P. Zhang, Brain biopsy in atypical dementia and primary angiitis of the central nervous system, Human Pathology, 51,146–147, (2016).

[2] , (2011). Paris, France: The International Union Against Tuberculosis and Lung Disease, 2011. http://documents.mx/documents/global-asthma-report-2011.html.Accessed 20 June 2016.

[3] N. Ait-Khaled, J. Odhiambo, N. Pearce, K. S. Adjoh, I. A. Maesano, B. Benhabyles, Z. Bouhayad, E. Bahati, L. Camara, C. Catteau, A. El Sony, F. O. Esamai, I. E. Hypolite, K. Melaku, O. A. Musa, L. Ng’ang’a, B. O. Onadeko, O. Saad, M. Jerray, J. M. Kayembe, N. B. Koffi, F. Khaldi, C. Kuaban, K. Voyi, J. M’Boussa, O. Sow, O. Tidjani, and H. J.
Zar, Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in Africa: The International Study of Asthma and Allergies in Childhood Phase III, Allergy: European Journal of Allergy and Clinical Immunology, 62, no. 3, 247–258, (2007).

[4] , BTS/SIGN Asthma Guideline (2014). https://www.brit-thoracic.org.uk/documentlibrary/clinical information/asthma/btssign-asthma-guideline-2014/. Accessed 2 July 2015.

[5] HA. Boushy, Drugs Used in Asthma. In: Katzung BG, Masters SB, Trevor AJ, editors. (2009). Basic and Clinical Pharmacology, 11th ed. USA: McGraw Hill;. p. 344-347.

[6] MR. Simpson, Benign joint hypermobility syndrome: evaluation, diagnosis, and management, The Journal of the American Osteopathic Association, 106, no. 9, 531– 536, (2006).

[7] R. Grahame, HA. Bird, and A. Child, The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS), J Rheumatol, 27, no. 7, 1777–1779, (1998).

[8] D. B. Everman and N. H. Robin, Hypermobility syndrome., Pediatrics in review / American Academy of Pediatrics, 19, no. 4, 111–117, (1998).

[9] L.-G. Larsson, J. Baum, G. S. Mudholkar, and G. D. Kollia, Benefits and disadvantages of joint hypermobility among musicians, The New England Journal of Medicine, 329, no. 15, 1079–1082, (1993).

[10] N. Adib, K. Davies, R. Grahame, P. Woo, and K. J. Murray, Joint hypermobility syndrome in childhood. A not so benign multisystem disorder? Rheumatology, 44, no. 6, 744–750, (2005).

[11] M. Castori, Ehlers-Danlos Syndrome, Hypermobility Type: An Underdiagnosed Hereditary Connective Tissue Disorder with Mucocutaneous, Articular, and Systemic Manifestations, ISRN Dermatology, 2012, 1–22, (2012).

[12] A.-M. Malfait, A. S. Malik, L. Marinova-Mutafchieva, D. M. Butler, R. N. Maini, and M. Feldmann, The β2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: Mechanisms of action, The Journal of Immunology, 162, no. 10, 6278–6283, (1999).

[13] P. Aránguiz-Urroz, J. Canales, M. Copaja, R. Troncoso, J. M. Vicencio, C. Carrillo, H. Lara, S. Lavandero, and G. Díaz-Araya, Beta2-adrenergic receptor regulates cardiac fibroblast autophagy and collagen degradation, Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease, 1812, no. 1, 23–31, (2011).

[14] A. W. Morgan, S. B. Pearson, S. Davies, H. C. Gooi, and H. A. Bird, Asthma and airways collapse in two heritable disorders of connective tissue, Annals of the Rheumatic Diseases, 66, no. 10, 1369–1373, (2007).

[15] E. Soyucen and F. Esen, Benign joint hypermobility syndrome: A cause of childhood asthma? Medical Hypotheses, 74, no. 5, 823–824, (2010).

[16] F. N. Birrell, A. O. Adebajo, B. L. Hazleman, and A. J. Silman, High prevalence of joint laxity in west africans, Rheumatology, 33, no. 1, 56–59, (1994).

[17] Z. S. Al-rawi, A. J. Al-aszawi, and T. Al-chalabi, Joint mobility among university students in Iraq, Rheumatology, 24, no. 4, 326–331, (1985).

[18] F. Biro, H. L. Gewanter, and J. Baum, THE HYPERMOBILITY SYNDROME, Journal of Pediatric Orthopaedics, 4, no. 2, p. 265, (1984).

[19] M. G. Hall, W. R. Ferrell, R. D. Sturrock, D. L. Hamblen, and R. H. Baxendale, The effect of the hypermobility syndrome on knee joint proprioception, British Journal of Rheumatology, 34, no. 2, 121–125, (1995).

[20] A. J. Hakim, L. F. Cherkas, R. Grahame, T. D. Spector, and A. J. MacGregor, The genetic epidemiology of joint hypermobility: a population study of female twins, Arthritis & Rheumatism, 50, no. 8, 2640–2644, (2004).

[21] Inc. GlaxoSmithKline, Salbutamol sulphate inhalation aerosol, PRODUCT MONOGRAPH April, 29, Article ID 171564, (2014)., http://ca.gsk.com/media/592944/ventolin-hfa.pdf.

[22] P. Klemp, S. M. Williams, and S. A. Stansfield, Articular mobility in Maori and European New Zealanders, Rheumatology, 41, no. 5, 554–557, (2002).

[23] M. B. Mishra, P. Ryan, P. Atkinson, H. Taylor, J. Bell, D. Calver, I. Fogelman, A. Child, G. Jackson, J. B. Chambers, and R. Grahame, Extra-articular features of benign joint hypermobility syndrome, British Journal of Rheumatology, 35, no. 9, 861–866, (1996).